Work

BiDil: Race Medicine Or Race Marketing?

Year: 2005

Type: article

Abstract: Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irrespective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the culiarities of U.S. patent law and willingness exploit race to gain commercial and regulatory advantage.

Source: Health Affairs

DOI: 10.1377/hlthaff.w5.455

Authors: Pamela Sankar, Jonathan Kahn

Institutions: University of Pennsylvania, Hamline University, Northeastern University

Language: English

Topic: Race, Genetics, and Society

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: green

Funder: National Human Genome Research Institute